Jazz Pharmaceuticals plc — Director's Dealing 2026

Mar 2, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2026-02-26

Reporting Person: Johnson Philip L (EVP & Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-26	Ordinary Shares	A	11857	$0.0	Acquired	62223	Direct

Footnotes

F1: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

F2: The Reporting Person acquired 166 ordinary shares on May 30, 2025 and 140 shares on November 28, 2025 under a Section 423 Employee Stock Purchase Plan.